These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 3082391)

  • 1. Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals.
    Noe DA; Bell WR; Ness PM; Levin J
    Blood; 1986 Apr; 67(4):969-72. PubMed ID: 3082391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
    Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
    Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the Detection of Factor IX Inhibitors in Hemophilia B Orphan than Factor VIII Inhibitors in Hemophilia A? A Concise, Systematic Review.
    Mansouritorghabeh H; Mohades ST
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(3):185-190. PubMed ID: 32611303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of continuous infusion of factor concentrates in the treatment of hemophilia.
    Bona RD; Weinstein RA; Weisman SJ; Bartolomeo A; Rickles FR
    Am J Hematol; 1989 Sep; 32(1):8-13. PubMed ID: 2502914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor.
    Repke D; Gemmell CH; Guha A; Turitto VT; Broze GJ; Nemerson Y
    Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7623-7. PubMed ID: 2120704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting TFPI for hemophilia treatment.
    Peterson JA; Maroney SA; Mast AE
    Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of self-therapy in hemophilia. A study of 72 patients with hemophilia A and B.
    Levine PH
    N Engl J Med; 1974 Dec; 291(26):1381-4. PubMed ID: 4427642
    [No Abstract]   [Full Text] [Related]  

  • 9. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven.
    Johannessen M; Andreasen RB; Nordfang O
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):239-42. PubMed ID: 10870803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.
    Iorio A; Blanchette V; Blatny J; Collins P; Fischer K; Neufeld E
    J Thromb Haemost; 2017 Dec; 15(12):2461-2465. PubMed ID: 29119666
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hemophilia].
    Shima M
    Rinsho Ketsueki; 2013 Feb; 54(2):189-97. PubMed ID: 23470826
    [No Abstract]   [Full Text] [Related]  

  • 12. Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?
    Hazendonk HCAM; van Moort I; Mathôt RAA; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH;
    Blood Rev; 2018 Jul; 32(4):265-271. PubMed ID: 29426727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of hemophilia].
    Straub PW
    Dtsch Med Wochenschr; 1969 Sep; 94(37):1885-7. PubMed ID: 5356323
    [No Abstract]   [Full Text] [Related]  

  • 14. Orthotopic liver transplantation in a patient with combined hemophilia A and B.
    Delorme MA; Adams PC; Grant D; Ghent CN; Walker IR; Wall WJ
    Am J Hematol; 1990 Feb; 33(2):136-8. PubMed ID: 2105634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
    Hay CR; Baglin TP; Collins PW; Hill FG; Keeling DM
    Br J Haematol; 2000 Oct; 111(1):78-90. PubMed ID: 11091185
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of factor VIII:C and factor IX activity in plasmas of haemophilic dogs on the activated partial thromboplastin time measured with two commercial reagents.
    Mischke R
    Haemophilia; 2000 May; 6(3):135-9. PubMed ID: 10792470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Substitution treatment in hemophilia. Critical measures and complications].
    Schimpf K
    Wien Med Wochenschr; 1977 Jun; 127(11):329-37. PubMed ID: 878496
    [No Abstract]   [Full Text] [Related]  

  • 19. Massive factor-VIII infusion in Haemophiliac with factor-VIII inhibitor, high responder. 1977.
    Brackmann HH; Gormsen J
    Haemophilia; 2010 May; 16(102):2-3. PubMed ID: 20536980
    [No Abstract]   [Full Text] [Related]  

  • 20. Problems involved in grading the severity of hemophilia by test results.
    Kaneda T; Nagayama M; Minato F; Nakahira H; Nakajima J; Shikimori M
    J Oral Surg; 1978 Dec; 36(12):956-9. PubMed ID: 309932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.